IDYA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

40.580

Open

39.230

VWAP

39.91

Vol

1.51M

Mkt Cap

3.90B

Low

38.630

Amount

60.14M

EV/EBITDA(TTM)

--

Total Shares

96.27M

EV

3.07B

EV/OCF(TTM)

--

P/S(TTM)

15.53

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

Show More

Events Timeline

(ET)

2026-06-17

07:00:00

Ideaya Biosciences Appoints Yujiro Hata as Chairman of the Board

2026-06-15 (ET)

2026-06-15

06:30:00

Ideaya Biosciences Begins Phase 1 Trial for IDE892

2026-06-08 (ET)

2026-06-08

19:20:00

Energy and Tech Sectors Perform Strong Amid Middle East Tensions

2026-06-03 (ET)

2026-06-03

06:10:00

Ideaya Enters Clinical Collaboration with Roche to Evaluate IDE892

2026-06-01 (ET)

2026-06-01

11:10:00

IDEAYA and Servier Present Darovasertib and Crizotinib Trial Data

News

PRnewswire

06-26PRnewswire

IDEAYA Grants 98,000 Stock Options to New Employees

Newsfilter

06-26Newsfilter

IDEAYA Grants 98,000 Stock Options to New Employees

NASDAQ.COM

06-17NASDAQ.COM

IDEAYA Biosciences Appoints New Chairman

PRnewswire

06-17PRnewswire

IDEAYA Biosciences Elects New Chairman of the Board

Newsfilter

06-17Newsfilter

IDEAYA Biosciences Appoints New Chairman

PRnewswire

06-15PRnewswire

IDEAYA Launches Phase 1 Trial for IDE892 in Cancer Treatment

15 Analyst Rating

Wall Street analysts forecast IDYA stock price to rise

13 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

49.86

High

79.00

Current: 0.000

Low

30.00

Averages

49.86

High

79.00

Truist

Gregory Renza

Buy

maintain

$65 -> $63

AI Analysis

2026-07-07

New

Reason

Truist

Gregory Renza

Price Target

$65 -> $63

AI Analysis

2026-07-07

New

maintain

Buy

Reason

Truist analyst Gregory Renza lowered the firm's price target on Ideaya Biosciences to $63 from $65 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.

RBC Capital

Outperform

downgrade

$53 -> $48

2026-07-07

New

Reason

RBC Capital

Price Target

$53 -> $48

2026-07-07

New

downgrade

Outperform

Reason

RBC Capital lowered the firm's price target on Ideaya Biosciences to $48 from $53 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P - driven by strong data expanding innovative spaces and perceptions around improving FDA flexibility/stability - and with outlooks more concretely definable than other high-volatility spaces, capital could continue to flow in, the analyst tells investors in a research note. Q2 earnings are shaping up to be seasonally strong, and with multiple opportunities for beats and the M&A resurgence likely to continue, there is little that would materially derail things, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IDYA

Unlock Now

Valuation Metrics

The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is 4.65, compared to its 5-year average forward P/E of -9.27. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-9.27

Current PE

4.65

Overvalued PE

-2.74

Undervalued PE

-15.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-7.45

Current EV/EBITDA

-1.90

Overvalued EV/EBITDA

1.74

Undervalued EV/EBITDA

-16.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

90.27

Current PS

32.45

Overvalued PS

183.85

Undervalued PS

-3.31

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 21 candidates

Market Cap: >= 500.00MRegion: USVolume: >= 500,000Analyst Consensus: Strong Buy, Moderate Buy, HoldRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

Eli Lilly and Co

1000.00B

Lam Research Corp

403.53B

AbbVie Inc

376.54B

General Electric Co

328.12B

Corning Inc

168.83B

General Dynamics Corp

93.20B

what stock should I buy now to day trade

Intellectia · 96 candidates

Region: USPrice: $5.00 - $80.00Price Change Pct: >= $4.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA5Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Corvex, Inc

727.42M

Leggett & Platt Inc

1.36B

LightPath Technologies Inc

740.40M

Lanzatech Global Inc

273.92M

Lightwave Logic Inc

1.58B

Edesa Biotech Inc

49.05M

Whales Holding IDYA

Logos Global Management, L.P.

Redmile Group, LLC

Deerfield Management Company, L.P.

Sofinnova Investments, Inc.

Tang Capital Management, LLC

General American Investors Company, Inc.

Trading Trends

People Also Watch

Frequently Asked Questions

What is IDEAYA Biosciences Inc (IDYA) stock price today?

The current price of IDYA is 40.51 USD — it has increased 2.9

What is IDEAYA Biosciences Inc (IDYA)'s business?

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.

What is the price predicton of IDYA Stock?

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is49.86 USD with a low forecast of 30.00 USD and a high forecast of 79.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is IDEAYA Biosciences Inc (IDYA)'s revenue for the last quarter?

IDEAYA Biosciences Inc revenue for the last quarter amounts to 6.56M USD, decreased

What is IDEAYA Biosciences Inc (IDYA)'s earnings per share (EPS) for the last quarter?

IDEAYA Biosciences Inc. EPS for the last quarter amounts to -1.11 USD, increased 35.37

How many employees does IDEAYA Biosciences Inc (IDYA). have?

IDEAYA Biosciences Inc (IDYA) has 145 emplpoyees as of July 08 2026.

What is IDEAYA Biosciences Inc (IDYA) market cap?

Today IDYA has the market capitalization of 3.90B USD.